ArticleFrontiers in oncology2021
Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network.
Open access · goldAbstract read
In one paragraph
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 13% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia.Leukemia · 2025Guideline
- Treatment patterns and clinical outcomes in chronic myeloid leukemia treated with second-line nilotinib-association of molecular milestones and prognostic scores with deep molecular response: a real-world retrospective cohort study.Sao Paulo medical journal = Revista paulista de medicina · 2026Article
- A comparison of the effect of three different comorbidity indices on overall survival in patients with chronic myeloid leukemia.Therapeutic advances in hematology · 2025Article
- Chronic Myeloid Leukemia Unveils Its Dark Side: A Rare Case of Megakaryocytic Blast Crisis.Cureus · 2024Article
- Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group.International journal of hematology · 2024Article
- Current Status and Management of Chronic Myeloid Leukemia in the Gulf Region: Survey Results and Expert Opinion.Cancers · 2024Article
- Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary.Pathology oncology research : POR · 2024Article
- Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights.Cells · 2023Review
- Prognostic Role of Cell Blood Count in Chronic Myeloid Neoplasm and Acute Myeloid Leukemia and Its Possible Implications in Hematopoietic Stem Cell Transplantation.Diagnostics (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
45 authors at 20 institutions in 1 country.
Giorgina SpecchiaFormer Full Professor of Hematology- University of Bari Aldo Moro" Bari GIMEMA WP CML, Bari, Italy.
Patrizia PregnoHaematology Unit, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Torino, Italy.
Massimo BrecciaDepartment of Cellular Biotechnologies and Hematology, Sapienza University of Rome, Roma, Italy.
Fausto CastagnettiDepartment of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
Chiara MonaghedduClinical Epidemiology Unit and CPO Piemonte, Città della Salute e della Scienza, Torino, Italy.
Massimiliano BonifacioSection of Hematology, Department of Medicine, University of Verona, Verona, Italy.
Mario TiribelliDivision of Hematology and BMT, Department of Medical Area, University of Udine, Udine, Italy.
Fabio StagnoDivision of Hematology and Bone Marrow Transplant, Azienda Ospedaliera-Universitaria (AOU) Policlinico-V. Emanuele, Catania, Italy.
Giovanni CaocciDepartment of Medical Sciences and Public Health, Businco Hospital, University of Cagliari, Cagliari, Italy.
Bruno MartinoHaematology Unit, Azienda Ospedaliera "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy.
Luigiana LucianoHaematology Unit "Federico II", University of Naples, Naples, Italy.
Michele PizzutiDepartment of Hematology, "San Carlo" Regional Hospital, Potenza, Italy.
Antonella GozziniHaematology Unit, AOU Careggi, University of Florence, Florence, Italy.
Anna Rita ScortechiniDivision of Hematology, Department of Molecular and Clinical Sciences, Polytechnic University of Marche, Ancona, Italy.
Francesco AlbanoDepartment of Emergency and Transplantation, Hematology Section, University of Bari Medical School, Bari, Italy.
Micaela BergamaschiClinical Hematology, Policlinico San Martino, Genua, Italy.
Isabella CapodannoDepartment of Hematology, Azienda UNITà SANITARIA LOCALE (USL)-IRCCS di Reggio Emilia, Viale Risorgimento, Reggio Emilia, Italy.
Andrea PatriarcaDivision of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
Carmen FavaDepartment of Clinical and Biological Sciences, University of Turin, Turin, Italy.
Giovanna Rege-CambrinOrbassano Hospital, Turin University, Turin, Italy.
Federica SoràInstitute of Hematology, Università Cattolica Sacro Cuore, Rome, Italy.
Sara GalimbertiDepartment of Clinical and Experimental Medicine, Unità Operativa (UO) Haematology, AOU Pisana, Pisa, Italy.
Monica BocchiaHaematology Unit, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy.
Gianni BinottoPadova Hematology and Clinical Immunology, Padua, Italy.
Giovanni ReddicontoDepartment of Ematologia, Lecce Ematologia Ospedale Vito Fazzi, Lecce, Italy.
Paolo DiTonnoHaematology Unit, National Cancer Center, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Alessandro MaggiDivision of Hematology, Hospital "S.G. Moscati", Taranto, Italy.
Grazia SanpaoloDepartment of Hematology and Stem Cell Transplantation Unit, IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy.
Maria Stella De CandiaHematology, Hospital A. Perrino, Brindisi, Italy.
Valentina GiaiHaematology Unit, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Torino, Italy.
Elisabetta AbruzzeseHemoglobinopathies Unit, Hematology Department, S. Eugenio Hospital (ASL Roma 2), Rome, Italy.
Maria Cristina MiggianoHematology Department, San Bortolo Hospital, Vicenza, Italy.
Gaetano La BarbaDepartment of Hematology, "Spirito Santo" Hospital, Pescara, Italy.
Giuseppe PietrantuonoHematology Oncology, IRCCS Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy.
Anna GuellaHematology Unit, Santa Chiara Hospital, Trento, Italy.
Luciano LevatoHaematology Unit, A. Pugliese Hospital, Azienda Ospedaliera Pugliese Ciaccio, Catanzaro, Italy.
Olga MulasDepartment of Medical Sciences and Public Health, Businco Hospital, University of Cagliari, Cagliari, Italy.
Fabio SacconaClinical Epidemiology Unit and CPO Piemonte, Città della Salute e della Scienza, Torino, Italy.
Gianantonio RostiDepartment of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
Pellegrino MustoDepartment of Emergency and Transplantation, Hematology Section, University of Bari Medical School, Bari, Italy.
Francesco Di RaimondoDivision of Hematology and Bone Marrow Transplant, Azienda Ospedaliera-Universitaria (AOU) Policlinico-V. Emanuele, Catania, Italy.
Fabrizio PaneHaematology Unit "Federico II", University of Naples, Naples, Italy.
Michele BaccaraniDepartment of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
Giuseppe SaglioDepartment of Clinical and Biological Sciences, University of Turin, Turin, Italy.
Giovannino CicconeClinical Epidemiology Unit and CPO Piemonte, Città della Salute e della Scienza, Torino, Italy.
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITUniversity of Bari Aldo Moro · ITPiedmont Reference Center for Epidemiology and Cancer Prevention · ITPoliclinico S.Orsola-Malpighi · ITUniversity of Cagliari · ITUniversity of Naples Federico II · ITUniversity of Turin · ITASL Roma · ITAzienda ospedaliera "Bianchi-Melacrino-Morelli" · ITAzienda Ospedaliera Pugliese Ciaccio · ITAzienda Ospedaliera S.Giuseppe Moscati · ITAzienda Sanitaria Unità Locale di Reggio Emilia · ITMarche Polytechnic University · ITOspedale A. Perrino · ITOspedale di Santo Spirito · ITOspedale Policlinico San Martino · ITOspedale San Bortolo · ITOspedale San Carlo · ITOspedale Santa Chiara · IT
Funding
No grant is acknowledged in the PubMed record.
Abstract
An observational prospective study was conducted by the CML Italian network to analyze the role of baseline patient characteristics and first line treatments on overall survival and CML-related mortality in 1206 newly diagnosed CML patients, 608 treated with imatinib (IMA) and 598 with 2
Indexed as
chronic myeloid leukemiaELTsprognostic factorsSokal scoretyrosine kinase inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.